SR 27897

Confirm delete?

SR 27897

Zoom

Cat No: 28511

Biochemicals - Receptor Pharmacology

SR 27897 is a nonpeptide cholecystokinin (CCK) receptor antagonist.{42981} It selectively binds to CCK1 receptors in rat pancreatic membranes (IC50 = 0.58 nM) over CCK2 receptors in guinea pig cortical membranes and gastrin receptors in guinea pig gas...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid

Correlated keywords:

1435934-52-3 SR-27897B SR27897B SR27897-B non-peptide CCK-1 2 pa-2

Product Overview:
SR 27897 is a nonpeptide cholecystokinin (CCK) receptor antagonist.{42981} It selectively binds to CCK1 receptors in rat pancreatic membranes (IC50 = 0.58 nM) over CCK2 receptors in guinea pig cortical membranes and gastrin receptors in guinea pig gastric gland suspensions (IC50s = 489 and 2,883 nM, respectively). SR 27897 inhibits amylase secretion induced by CCK in isolated rat pancreatic acini (pA2 = 7.50) and CCK-induced guinea pig gallbladder contractions ex vivo (pA2 = 9.57). It completely reverses CCK-induced amylase secretion in rats when administered at a dose of 1 mg/kg. SR 27897 also inhibits CCK-induced gastric and gallbladder emptying in mice (ED50s = 3 and 72 μg/kg, respectively). SR 27897 inhibits gallbladder emptying in a mouse model of egg yolk-stimulated endogenous CCK release (ED50 = 27 μg/kg).

Size	5 mg
Shipping	dry ice
CAS Number	136381-85-6
Molecular Formula	C₂₀H₁₄ClN₃O₃S
SMILES	O=C(NC1=NC(C2=CC=CC=C2Cl)=CS1)C3=CC4=CC=CC=C4N3CC(O)=O
Molecular Weight	411,9
Formulation	A solid
Purity	≥98%
Custom Code	2934.10
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.